LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

Home・Aandelen Lijst・Pulse Biosciences Inc

Pulse Biosciences Inc

Gesloten

SectorGezondheidszorg

15.21 -0.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

15.1

Max

15.84

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.4M -19M
EPS	-0.28
Winstmarge	-2,018.63
Werknemers	75
EBITDA	-857K -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+43.23% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	137M 1.1B
Vorige openingsprijs	16.19
Vorige sluitingsprijs	15.21

Nieuwssentiment

By Acuity

67%

33%

332 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

16.59 / 17.17 Steun & Weerstand

Pulse Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 nov 2025, 23:59 UTC

Winsten

Singtel's 1st Half Net Profit Surges

11 nov 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 nov 2025, 22:21 UTC

Winsten

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 nov 2025, 23:52 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 nov 2025, 23:44 UTC

Winsten

Singtel's 1H Net Profit Surges

11 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 nov 2025, 23:18 UTC

Winsten

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 nov 2025, 23:15 UTC

Winsten

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 nov 2025, 23:14 UTC

Winsten

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 nov 2025, 23:12 UTC

Winsten

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 nov 2025, 23:11 UTC

Winsten

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 nov 2025, 23:10 UTC

Winsten

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 nov 2025, 23:04 UTC

Marktinformatie

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Health Care Roundup: Market Talk

11 nov 2025, 21:46 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 nov 2025, 21:41 UTC

Winsten

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 nov 2025, 21:40 UTC

Winsten

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: Final Dividend 49 Australian Cents/Share

11 nov 2025, 21:37 UTC

Winsten

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 nov 2025, 21:36 UTC

Winsten

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 nov 2025, 21:35 UTC

Winsten

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Adj EPS 79c >ALC

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Rev $2.61B >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q EPS 48c >ALC.EB

Peer Vergelijking

Prijswijziging

Pulse Biosciences Inc Prognose

Koersdoel

By TipRanks

43.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22 USD 43.23%

Hoogste 22 USD

Laagste 22 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pulse Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Pulse Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

16.59 / 17.17Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

332 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.